JP2023537066A - トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 - Google Patents

トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 Download PDF

Info

Publication number
JP2023537066A
JP2023537066A JP2023508513A JP2023508513A JP2023537066A JP 2023537066 A JP2023537066 A JP 2023537066A JP 2023508513 A JP2023508513 A JP 2023508513A JP 2023508513 A JP2023508513 A JP 2023508513A JP 2023537066 A JP2023537066 A JP 2023537066A
Authority
JP
Japan
Prior art keywords
payload
alkylene
pharmaceutically acceptable
acceptable salt
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023508513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537066A5 (enExample
Inventor
メヒア・オネト，ホセ・マヌエル
イー，ネイサン・エイ
スリニバサン，サンギータ
ザハリャン，マイケル
マクファーランド，ジェシー・エム
Original Assignee
タンボ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タンボ・インコーポレイテッド filed Critical タンボ・インコーポレイテッド
Publication of JP2023537066A publication Critical patent/JP2023537066A/ja
Publication of JP2023537066A5 publication Critical patent/JP2023537066A5/ja
Priority to JP2026054436A priority Critical patent/JP2026125614A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2023508513A 2020-08-07 2021-08-06 トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 Pending JP2023537066A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026054436A JP2026125614A (ja) 2020-08-07 2026-03-27 トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063062814P 2020-08-07 2020-08-07
US63/062,814 2020-08-07
PCT/US2021/045100 WO2022032191A1 (en) 2020-08-07 2021-08-06 Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026054436A Division JP2026125614A (ja) 2020-08-07 2026-03-27 トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Publications (2)

Publication Number Publication Date
JP2023537066A true JP2023537066A (ja) 2023-08-30
JP2023537066A5 JP2023537066A5 (enExample) 2024-08-14

Family

ID=77543672

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023508513A Pending JP2023537066A (ja) 2020-08-07 2021-08-06 トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
JP2026054436A Pending JP2026125614A (ja) 2020-08-07 2026-03-27 トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026054436A Pending JP2026125614A (ja) 2020-08-07 2026-03-27 トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Country Status (5)

Country Link
US (2) US12589162B2 (enExample)
EP (2) EP4192506A1 (enExample)
JP (2) JP2023537066A (enExample)
CN (1) CN116056765A (enExample)
WO (1) WO2022032191A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077129A1 (en) 2021-10-29 2023-05-04 Tambo, Inc. Tetrazine conjugates for in vivo targeted delivery of a payload
JP2025531342A (ja) 2022-09-20 2025-09-19 バランクス・バイオテック・ゲーエムベーハー タンパク質およびペプチドにおけるクリック－トゥ－リリース
JP2026508188A (ja) * 2023-02-21 2026-03-10 タンボ・インコーポレイテッド トランス－シクロオクテンコンジュゲート
EP4704904A1 (en) 2023-05-04 2026-03-11 Tambo, Inc. Tetrazine-based targeting agents for in vivo delivery of a payload
EP4713022A1 (en) 2023-05-18 2026-03-25 Tambo, Inc. Trans-cyclooctene-modified targeted protein degrader conjugates
EP4750750A1 (en) * 2023-07-27 2026-06-03 Veraxa Biotech GmbH Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
CN122138843A (zh) 2023-09-15 2026-06-02 坦博公司 用于有效载荷的体内靶向递送的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515039A (ja) * 2011-05-16 2014-06-26 コーニンクレッカ フィリップス エヌ ヴェ 生体直交型薬物活性化
JP2020516621A (ja) * 2017-04-07 2020-06-11 タンボ・インコーポレイテッド 生体直交型組成物
JP2022538690A (ja) * 2019-07-05 2022-09-05 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
US7662368B2 (en) 1999-07-16 2010-02-16 Institut Pasteur Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CA2447594A1 (en) 2001-06-21 2003-01-03 Clontech Laboratories, Inc. Water-soluble polymeric metal ion affinity compositions and methods for using the same
AU2003221078A1 (en) 2002-04-08 2003-10-20 Denki Kagaku Kogyo Kabushiki Kaisha Therapeutic composition for bone infectious disease
US7445894B2 (en) 2002-05-03 2008-11-04 Molecular Probes, Inc. Compositions and methods for detection and isolation of phosphorylated molecules
EP1651162B1 (en) 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
WO2007052267A2 (en) 2005-11-01 2007-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
EP2017281A4 (en) 2006-04-14 2012-03-14 Kyowa Hakko Kirin Co Ltd AGONISTS AT TOLL-LIKE RECEPTOR 9
EP1867638A1 (de) 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8236949B2 (en) 2007-07-17 2012-08-07 University Of Delaware Tetrazine-based bio-orthogonal coupling reagents and methods
CA2693266C (en) 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
JP5574083B2 (ja) 2008-08-01 2014-08-20 アンタイス エス．エイ． 高い残留性及び容量を与える高い能力を有する注入可能なヒドロゲル
CN102271712B (zh) 2008-10-31 2015-11-25 通用医疗公司 用于将物质递送至生物靶标的组合物和方法
US20110223257A1 (en) 2008-11-17 2011-09-15 Enzon Pharmaceuticals, Inc. Releasable fusogenic lipids for nucleic acids delivery systems
JP2012516352A (ja) 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
WO2010119389A2 (en) 2009-04-16 2010-10-21 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
EP2360167A1 (en) 2010-02-03 2011-08-24 Deutsches Krebsforschungszentrum Post-synthetic modification of nucleic acids by inverse Diels-Alder reaction
CN103221398B (zh) 2010-07-23 2016-03-23 特拉华大学 用于快速构建放射性核素标记探针的四嗪-反式环辛烯连接反应
WO2012049624A1 (en) 2010-10-14 2012-04-19 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
JP5992435B2 (ja) 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 循環からの生体分子の除去剤
EP2522369A1 (en) 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
US20140256831A1 (en) 2011-05-31 2014-09-11 The University Of Tokyo Hydrogel and method for producing same
ES2393602B1 (es) 2011-06-09 2013-10-02 Universidad Complutense De Madrid Materiales biocerámicos para el tratamiento de la osteomielitis.
WO2013115885A2 (en) 2011-11-22 2013-08-08 The Regents Of The University Of Michigan Synthesizing functionalized dendrimers within biological settings
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US9206271B2 (en) 2012-03-25 2015-12-08 Wisconsin Alumni Research Foundation Fully backbone degradable and functionalizable polymers derived from the ring-opening metathesis polymerization (ROMP)
US10274490B2 (en) 2012-06-12 2019-04-30 The General Hospital Corporation Magnetic labeling of bacteria
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
US10927139B2 (en) 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US20150359913A1 (en) 2013-01-25 2015-12-17 Memorial Sloan-Kettering Cancer Center Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
WO2014138186A1 (en) 2013-03-05 2014-09-12 The Johns Hopkins University Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics
FI2964224T3 (fi) 2013-03-08 2024-09-27 Polyactiva Pty Ltd Polymeerikonjugaatti bioaktiivisen aineen annostelemiseksi
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
JP6600302B2 (ja) 2013-06-12 2019-10-30 ザ ジェネラル ホスピタル コーポレイション 標的分子のマルチプレックス検出のための方法、キット、およびシステム、ならびにそれらの使用
EP3010486B1 (en) 2013-06-19 2023-11-22 The Regents of The University of California Chemical structures for localized delivery of therapeutic agents
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
WO2015117235A1 (en) 2014-02-10 2015-08-13 Mcmaster University Targeted molecular imaging contrast agents
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
AU2015229014B2 (en) 2014-03-14 2019-07-25 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
JP6787789B2 (ja) 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
EP3125960B1 (en) 2014-04-04 2020-06-03 President and Fellows of Harvard College Click-crosslinked hydrogels and methods of use
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
WO2016014799A1 (en) 2014-07-23 2016-01-28 University Of Iowa Research Foundation Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
CN108135857A (zh) 2015-09-10 2018-06-08 沙思奇公司 生物正交组合物
KR20180066241A (ko) 2015-10-28 2018-06-18 아두로 바이오테크, 인코포레이티드 “인터페론 유전자의 자극제”-의존성 신호전달을 활성화시키기 위한 조성물 및 방법
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド
SMT202500412T1 (it) 2016-01-11 2025-11-10 Innate Tumor Immunity Inc Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
RU2725292C2 (ru) * 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CA3029644A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
SG11201900154VA (en) 2016-07-15 2019-02-27 Sperovie Biosciences Inc Compounds, compositions, and methods for the treatment of disease
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
JP6636673B2 (ja) 2016-10-04 2020-01-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＳＴＩＮＧアゴニストとしてのベンゾ［ｂ］チオフェン化合物
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
ES2924186T3 (es) 2017-01-27 2022-10-05 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de STING
ES2891326T3 (es) 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US20200138827A1 (en) 2017-06-22 2020-05-07 Curadev Pharma Limited Small molecule modulators of human sting
JP2020524718A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
CN111601900A (zh) 2017-11-02 2020-08-28 詹森生物制药有限公司 寡核苷酸构建体及其用途
PH12020550585A1 (en) 2017-11-10 2021-04-19 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
MX2020006290A (es) 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
PL3700564T3 (pl) 2017-12-15 2026-02-23 Elanco Animal Health Gmbh Kompozycje immunostymulujące
WO2019123338A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
AU2019262521B2 (en) * 2018-05-04 2024-04-18 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
CN110496233B (zh) * 2019-09-05 2022-07-19 复旦大学附属中山医院 一种spect显像剂及其标记前体及其制备方法、组合物和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515039A (ja) * 2011-05-16 2014-06-26 コーニンクレッカ フィリップス エヌ ヴェ 生体直交型薬物活性化
JP2020516621A (ja) * 2017-04-07 2020-06-11 タンボ・インコーポレイテッド 生体直交型組成物
JP2022538690A (ja) * 2019-07-05 2022-09-05 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADVANCED THERAPEUTICS, vol. 4, no. 3, JPN6025025963, 20 January 2021 (2021-01-20), ISSN: 0005627606 *
NATURE NANOTECHNOLOGY, vol. 5, no. 9, JPN6025025964, 2010, pages 660 - 665, ISSN: 0005627607 *

Also Published As

Publication number Publication date
US20230256109A1 (en) 2023-08-17
US20260007759A1 (en) 2026-01-08
EP4295917A2 (en) 2023-12-27
WO2022032191A1 (en) 2022-02-10
JP2026125614A (ja) 2026-08-03
EP4295917A3 (en) 2024-02-28
US12589162B2 (en) 2026-03-31
CN116056765A (zh) 2023-05-02
EP4192506A1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
US12589162B2 (en) Trans-cyclooctene prodrug of monomethyl auristatin E
US12611461B2 (en) Bioorthogonal compositions
JP7622031B2 (ja) トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
US20250186592A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
EP4422693A1 (en) Trans-cyclooctene conjugates
HK40104832A (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
JP2026508188A (ja) トランス－シクロオクテンコンジュゲート
HK40109540A (zh) 反式环辛烯缀合物
WO2024229427A1 (en) Tetrazine-based targeting agents for in vivo delivery of a payload
WO2024238969A1 (en) Trans-cyclooctene-modified targeted protein degrader conjugates
HK40108922A (en) Tetrazine conjugates for in vivo targeted delivery of a payload
WO2025059685A1 (en) Methods for in vivo targeted delivery of a payload

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260330